The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AMLVeronica Novotny‐Diermayr, J M Wood|Blood Cancer Journal|2012Cited by 99